

SCHOTT Pharma | 2025


# Facts & Figures



## Global Footprint

17 state-of-the-art production facilities (incl. 4 Joint Ventures)

15 countries, including all major pharma hubs



100% focus  
on our core expertise

Pharma drug containment and  
delivery solutions



€986

million revenue  
(+5.8% at constant  
currencies)

€280

million EBITDA  
Margin: 28.4 %



>1,300

patents, patent applications,  
utility models, and designs  
filed by R&D team

125

employees  
active in R&D collaborating  
with an exclusive network  
of partners

On average, more than 30,000 injections per minute  
are provided to patients worldwide through a SCHOTT Pharma product.

>13

billion products  
delivered every year



Glass  
syringes



Polymer  
syringes



Cartridges



Vials



Ampoules



Broad  
ready-to-use  
portfolio



# Market & Customers

The **top 30** global pharma companies use SCHOTT Pharma's solutions.

**>1,800**

customers worldwide



Big pharma innovators



Leading CDMOs



Biotechs & start-ups

## Growth opportunities from structural trends

### GLP-1 drugs

Increasing demand to treat type-2 diabetes, obesity



SCHOTT Pharma has long-term contracts with the leading GLP-1 players

### Antibody-drug conjugates (ADCs)

Innovative ADC therapies need to be lyophilized to ensure drug efficacy



SCHOTT Pharma offers specialty vials that fully eliminate fogging thanks to a hydrophobic inner coating

### Homecare solutions

allow subcutaneous self-injection of small and large drug doses at home, thus reducing healthcare cost



SCHOTT Pharma contributes to fully integrated systems from device manufacturers with primary packaging, e.g. prefillable syringes and cartridges in small and large formats

### Manufacturing transformation

Smaller patient populations require more flexible filling lines



SCHOTT Pharma offers pre-sterilized, ready-to-use products for utmost flexibility

<sup>1</sup>No competitor disclosed a product with mentioned specifications so far



# SCHOTT Pharma

## ESG Responsibility



**60%**  
reduced CO<sub>2</sub>  
emissions since 2019<sup>1</sup>

**100 %**  
Already using green  
electricity worldwide



Closed-loop  
recycling pilot  
projects started  
e.g. polymer trays for  
vials

Vials with reduced product  
carbon footprint  
available from 2027<sup>2</sup>



**~4.800**

employees from over

**>65**

nationalities

**>40%**

female employees

**~23 %**

of leadership positions  
held by women



### Ownership



### Executive Board



**Andreas Reisse**  
CEO

Over 35 years of experience

Heading SCHOTT's pharma  
business since 2010

Previously headed SCHOTT's  
Tubing business unit

Master's Degree in Industrial  
Engineering



**Reinhard Mayer**  
CFO

Over 30 years of experience

CFO of SCHOTT Pharma since 2025

Previous CFO roles with Nilfisk  
Holding, Hansgrohe, and Geringe  
Group

Master's Degree in Industrial  
Engineering

<sup>1</sup> Scope 1 & 2; Defined as corporate CO<sub>2</sub> footprint of SCHOTT Pharma divided by number of good pieces sold (as of FY 2022)  
<sup>2</sup> Approximately 30% CO<sub>2</sub> reduction for a 2 ml vial compared to current technology



# SCHOTT Pharma's Governance

**KGaA** (Kommanditgesellschaft auf Aktien) is a listed partnership limited by shares with three corporate bodies:



**General partner**  
(Komplementär)



**Supervisory board**  
(Aufsichtsrat)



**General shareholders' meeting**  
(Hauptversammlung)

As a **popular legal form** for companies originating from families or foundations, there are many **established KGaA** in Germany.

## Supervisory Board

Shareholder representatives



**Chairman**  
**Peter Goldschmidt**  
CEO  
Stada AG



**Deputy Chairman**  
**Dr. Wolfram Carius**  
Executive Vice President  
Bayer AG



**Eva Kienle**  
CFO  
KWS Saat SE & Co. KGaA



**Ann-Kristin Erkens**  
CFO  
SIG Group AG

## Employee representatives



**Mario Just**  
SCHOTT Pharma



**Isabel Deister**  
SCHOTT Pharma

## Press contact



**Lea Kaiser**



[lea.kaiser@schott.com](mailto:lea.kaiser@schott.com)



+49 (0) 151/68 91 71 95



**Katrin Schreyer**



[katrin.schreyer@schott.com](mailto:katrin.schreyer@schott.com)



+49 (0) 171/11 67 54 4

